Abount us

Member

Katsuhisa HORIMOTO, Ph.D.

Board Director CEO, Founder

Tokyo Univ. of Science, Ph.D.(Biophysics),The Univ. of Tokyo, AIST
>130 peer-reviewed papers on computational systems biology, 8 parents of algorithms.
2017/9 Co-founder of SOCIUM.
2019/4 Visiting Professor of Saitama Medical Univ.

Michio SHIGEMORI, MBA

Board Director, CFO

Meiji Univ., MBA
Worked in global treasury services at Bank of America and treasury operations at BASF Metals Japan.
2022/6 Joined SOCIUM
2024/1 Board Director CFO

Tadashi HORIUCHI, Ph.D.

Outside Director

Worked in Daiichi Pharmaceutical Co., Ltd (currently Daiichi Sankyo Co., Ltd.) and Asubio Pharma Co., Ltd. (currently Daiichi Sankyo Co., Ltd.).
2008/4 Senior Coodinator of Center for Research Promotion, Comprehensive Research Promotion Organization, Keio University
2016/4 Guest Professor of Clinical & Translational Research Center, Keio University Hospital
2017/9 Science and Technical Advisor, Japan Agency for Medical Research and Development
2024/7 joined SOCIUM

Makoto MIURA

Audit & Supervisory Board Member

Graduated from the Univ. of Tokyo, Faculty of Economics.
Worked in U.S. GAAP auditing of megabanks at Deloitte Touche Tohmatsu LLC and Established Makoto Miura CPA Office.
2018/10 Joined SOCIUM

Company Profile

Segments	① Drug repositioning platform based on a combination of proprietary technologies, and the world’s first phosphorylation analysis technology ・Drug Repurposing（Indication Hopping）・Phosphorylation Analysis（activating pathway and kinase analysis）・MOA Clarification ・Target Prediction ・Stratification Marker Exploration ・in vitro, vivo assay ② Joint development of drug seeds discovered using these technologies
Foundation date	Sep. 2017
CEO	Katsuhisa Horimoto
Office	17-1, Nihonbashi-Kabuto-cho, Chuo-ku, Tokyo 103-0026, Japan
Laboratory	AIST Tokyo Waterfront, 2-4-7, Aomi, Koto-ku, Tokyo 135-0064, Japan

Career

Click here for Career Information